Active, not recruitingPhase 2NCT07142811
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
Studying Hepatitis delta
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vir Biotechnology, Inc.
- Intervention
- Tobevibart(drug)
- Enrollment
- 100 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2025 – 2030
Study locations (25)
- Investigative Site, Brussels, Belgium
- Investigative Site, Edegem, Belgium
- Investigative Site, Sofia, Bulgaria
- Investigative Site, Stara Zagora, Bulgaria
- Investigative Site, Clichy, France
- Investigative Site, Créteil, France
- Investigative Site, Limoges, France
- Investigative Site, Rennes, France
- Investigative Site, Toulouse, France
- Investigative Site, Hanover, Germany
- Investigative Site, Chisinau, Moldova
- Investigative Site, Amsterdam, Netherlands
- Investigative Site, Nijmegen, Netherlands
- Investigative Site, Rotterdam, Netherlands
- Investigative Site, Karachi, Pakistan
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07142811 on ClinicalTrials.govOther trials for Hepatitis delta
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07454837Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideMirum Pharmaceuticals, Inc.
- RECRUITINGNCT07491848Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+DResearch Center of Periodontal-Systemic Interactions
- RECRUITINGPHASE3NCT07298330A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)Mirum Pharmaceuticals, Inc.
- RECRUITINGNCT07317011"Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGNCT07429864Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With BulvertideFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE3NCT07200908A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)Mirum Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07096193Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta VirusGilead Sciences
- RECRUITINGPHASE3NCT07128550A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideVir Biotechnology, Inc.